Reactions Weekly

, Volume 1696, Issue 1, pp 358–358 | Cite as

Vedolizumab

Fatal Pneumocystis jiroveci pneumonia and an unspecified opportunistic infection: 2 case reports
Case report
  • 28 Downloads

Reference

  1. Ng SC, et al. Vedolizumab clinical and post-marketing safety experience of opportunistic infections. Journal of Crohn's and Colitis 11 (Suppl. 1): S41 abstr. DOP024, Feb 2017. Available from: URL: https://doi.org/10.1093/ecco-jcc/jjx002.061 [abstract] - Hong Kong

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Personalised recommendations